T. Sunaga

First-line systemic treatment for people with extensive-stage small cell lung cancer: a network meta-analysis.

RATIONALE Extensive-stage small cell lung cancer (SCLC) carries a poor prognosis and has limited therapeutic options. The addition of immune-checkpoint inhibitors (ICIs) to platinum-etoposide (PE) chemotherapy has become an important first-line treatment strategy. However, the comparative benefits and harms of differen...